在ICS/LABA治疗中添加LAMA:COPD三联疗法荟萃分析
结果显示三联疗法显著改善 trough FEV1(+104.86 mL)并降低AECOPD风险(RR 0.78),且不增加心血管严重不良事件风险。
要点
- 三联疗法较ICS/LABA显著改善 trough FEV1,平均差+104.86 mL。
- 三联疗法降低AECOPD风险,RR 0.78(95%CI 0.71-0.85)。
- 添加LAMA不增加心血管严重不良事件风险,证据质量中等。
核心结论
- 在ICS/LABA基础上加用LAMA可显著改善COPD患者肺功能并减少急性加重,且不增加心血管严重不良事件风险。
主要发现
- 三联疗法较ICS/LABA改善 trough FEV1,平均差+104.86 mL(95%CI 86.74-122.99),证据质量高。
- 三联疗法降低AECOPD风险,相对风险0.78(95%CI 0.71-0.85),证据质量高。
- 每约4例接受三联疗法的患者中1例FEV1增加>100 mL;每约26例治疗1年可预防1次AECOPD。
- 添加LAMA未调节心血管严重不良事件风险,证据质量中等。
临床怎么用
- 对于正在使用ICS/LABA的COPD患者,可考虑升级为三联疗法以改善肺功能并减少急性加重。
- 升级三联疗法时无需过度担忧心血管严重不良事件风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) combination is commonly prescribed to treat COPD; therefore, we performed a meta-analysis on the effect of adding a long-acting muscarinic receptor antagonist (LAMA) to ICS/LABA combination in COPD. METHODS: Studies were identified by searching in different databases the randomized controlled trials that investigated the effect of ICS/LABA/LAMA combination in COPD. The primary end points were the effect of triple therapy on trough FEV1, risk of acute exacerbation of COPD (AECOPD), and risk of cardiovascular serious adverse events (SAEs), compared with ICS/LABA combination. The Grading of Recommendations Assessment, Development, and Evaluation system was used to assess the quality of evidence. RESULTS: Thirteen randomized controlled trials including 15,519 patients with COPD (ICS/LABA/LAMA combination, 53.1%; ICS/LABA combination, 46.9%) were meta-analyzed. ICS/LABA/LAMA combination improved trough FEV1 (mean difference, +104.86 mL; 95% CI, 86.74-122.99; high quality of evidence) and protected against AECOPD (relative risk, 0.78; 95% CI, 0.71-0.85; high quality of evidence) vs ICS/LABA combination. For every approximately four patients treated with triple therapy, one increased FEV1 > 100 mL, and approximately 26 patients had to be treated for 1 year with ICS/LABA/LAMA combination to prevent one AECOPD, compared with ICS/LABA combination. Adding a LAMA to ICS/LABA therapy did not modulate the risk of cardiovascular SAEs (moderate quality of evidence). CONCLUSIONS: Triple therapy provides significant clinical benefit in patients with COPD on ICS/LABA combination. ICS/LABA therapy can be escalated to triple therapy without a real risk to increase cardiovascular SAEs when a LAMA is added to the combination. TRIAL REGISTRY: ClinicalTrials.gov; No.: CRD42018095300; URL: www.clinicaltrials.gov.
引用
- Calzetta L, Cazzola M, Matera MG, et al. Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD. Chest. 2019. PMID: 30660781. doi:10.1016/j.chest.2018.12.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。